5th Generation HIV
Individual reporting of HIV-1, HIV-2, p24 antigen

The focus given to testing for HIV continues. HIV is one of the fastest growing serious health conditions in the UK. A total of 6151 people were newly diagnosed with HIV in the UK during 2014. 55% were among men who have sex with men (MSM). The challenge for the UK lies in timely diagnosis in order to start treatment. Two out of five people newly diagnosed had late stage HIV. Being diagnosed late is associated with a tenfold risk of death within one year of diagnosis.* 


TDL has introduced a next generation HIV assay with the Bio-Rad BioPlex 2200 HIV Ag-Ab assay. This is the first commercial screening assay to be able to distinguish between HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen in serum or plasma samples. In addition to the early detection offered by 4th generation assays, this 5th Generation assay provides more information by specifically identifying HIV-1 or HIV-2 and allows results of antigen and antibody detection to be reported individually. Because antigens and antibodies are detectable at different stages of the infection, reporting of both helps to differentiate between acute and established HIV infection. HIV-1 and HIV-2 are the two types of HIV, with HIV-1 being the most widespread worldwide. The two viruses are similar but distinct and different, which means that tests targeted to one type, will not detect the other.


*Public Health England (PHE) 


This 5th Generation HIV test is:

  • One of the best performers for detecting primary HIV infection 
  • Set at the same price as 4th Gen HDUO
  • Useful in a confirmatory algorithm with the advantage of differentiating the individual HIV analytes
  • CE marked and evaluated by PHE



TestCodeSample TypeTurnaround Time
HIV (5th Generation) Ag-Ab Screen (Bio-Rad BioPlex 2200)
Results report the following:
HIV-1 Abs, HIV-2 Abs, HIV-1 p24 Antigen
HIV5 B SST/Serum or
B TDL Tiny
24 hours